-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 28, the CDE official website showed that Junshi Bio's KRAS inhibitor JS116 applied for clinical application in China for the first time
JS116 is a small-molecule, irreversible covalent inhibitor of KRASG12C with a new structure for the treatment of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC)
In November 2020, the company signed the "Technology License and Cooperation Agreement" with Chengdu Huajian Future Technology Co.
Although the world's first KRAS inhibitor was only approved by the FDA in May 2021, based on the excellent potential in this field, there are already many companies deployed, and the competition is quite fierce.
KRASG12C target details
From: Insight database (http://db.